专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20060019336A1 Factor VII or VIIa - like molecules 失效
标题翻译：因子VII或VIIa样分子
公开(公告)号：US20060019336A1
公开(公告)日：2006-01-26
申请号：US10950747
申请日：2004-09-27
申请人： Anders Pedersen , Kim Andersen , Claus Bornaes
发明人： Anders Pedersen , Kim Andersen , Claus Bornaes
IPC分类号： C07K14/755 , C07H21/04 , C12P21/06
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
摘要翻译：提供因子VII（FVII）和因子VIIa（FVIIA）的缀合物，以及制备它们的方法。提供了有助于制备这种缀合物的新型多肽的制备方法。提供了通过施用FVII或FVIIa缀合物治疗的方法。

22. 发明申请

US20050201982A1 Polynucleotides encoding interferon gamma peptide variants 失效
标题翻译：编码干扰素γ肽变体的多核苷酸
公开(公告)号：US20050201982A1
公开(公告)日：2005-09-15
申请号：US11115906
申请日：2005-04-27
申请人： Bart Hazel , Anne Jensen , Frank Nygaard , Kim Anderson
发明人： Bart Hazel , Anne Jensen , Frank Nygaard , Kim Anderson
IPC分类号： A61K38/00 , C07K14/57 , A61K38/21 , C12P21/04
CPC分类号： C07K14/57 , A61K38/00
摘要： When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells. More particularly, the present invention relates to an IFNG polypeptide variant exhibiting IFNG activity and having the amino acid sequence shown in SEQ ID NO:12. In a highly preferred embodiment of the invention, the variant comprises at least one further modification, such as 1-10 further modifications, relative to the amino acid sequence shown in SEQ ID NO:12. A particular preferred further modification is E38N+S40T.
摘要翻译：当在哺乳动物细胞系中产生干扰素γ（IFNG）时，由于IFNG多肽的C末端加工，获得IFNG多肽的异源群体。显然，这构成了一个严重的问题，即有价值的多肽材料丢失，而且还需要进行耗时且繁琐的纯化，以获得具有所需长度的活性IFNG多肽的均质群体。现在已经发现，含有132个氨基酸残基的IFNG片段（在编码氨基酸残基132号的密码子后通过引入终止密码子在核苷酸水平被截短）不经历C-末端截短，或至少是不显着C末端截断。此外，由于含有132个氨基酸残基的IFNG片段是有活性的，因此可以在真核宿主细胞如CHO细胞中产生均一的活性IFNG多肽。更具体地，本发明涉及表现出IFNG活性且具有SEQ ID NO：12所示氨基酸序列的IFNG多肽变体。在本发明的一个非常优选的实施方案中，相对于SEQ ID NO：12所示的氨基酸序列，变体包含至少一个其它修饰，例如1-10个其它修饰。特别优选的进一步修改是E38N + S40T。

23. 发明申请

US20050095684A1 G-CSF conjugates 审中-公开
标题翻译： G-CSF缀合物
公开(公告)号：US20050095684A1
公开(公告)日：2005-05-05
申请号：US11004461
申请日：2004-12-03
申请人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
发明人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
IPC分类号： A61K38/00 , A61K47/42 , C07K14/53 , C07K14/535 , C12P21/02 , C07H21/04
CPC分类号： C07K14/535 , A61K9/0019 , A61K38/00 , A61K47/42 , C07K14/53
摘要： Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.
摘要翻译：具有G-CSF活性的多肽缀合物包含与人G-CSF序列相比具有至少一个引入的赖氨酸残基和至少一个去除的赖氨酸残基的多肽，并与2-6个聚乙二醇部分缀合。缀合物具有低的体外生物活性，长的体内半衰期，减少的受体介导的清除，并且提供比非共轭重组人G-CSF更快速地刺激白细胞和嗜中性粒细胞的产生。

24. 发明申请

US20030158375A1 G-CSF polypeptides and conjugates 审中-公开
标题翻译： G-CSF多肽和缀合物
公开(公告)号：US20030158375A1
公开(公告)日：2003-08-21
申请号：US10318966
申请日：2002-12-13
申请人： Maxygen Holdings, Ltd.
发明人： Torben Lauesgaard Nissen , Kim Vilbour Andersen , Christian Karsten Hansen , Jan Moller Mikkelsen , Hans Thalsgaard Schambye
IPC分类号： C12Q001/68 , A61K039/395 , C07K002/00 , C07K004/00 , C07K005/00 , C07K007/00 , C07K014/00 , C07K016/00 , C07K017/00 , A61K038/00 , C07K001/00
CPC分类号： C07K14/535 , A61K9/0019 , A61K38/00 , A61K47/42 , A61K47/60 , A61K47/61 , C07K14/53
摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.
摘要翻译：本发明涉及多肽缀合物，其包含显示G-CSF活性的多肽，并且具有不同于至少一个指定的引入和/或去除的氨基酸残基中的人G-CSF的氨基酸序列的氨基酸序列，所述氨基酸残基包含用于非多肽部分，并且具有连接到多肽的连接基团的至少一个非多肽部分。附件组可以例如。是赖氨酸，半胱氨酸，天冬氨酸或谷氨酸残基或糖基化位点，并且非多肽部分可以是例如。作为聚合物如聚乙二醇或寡糖。与hG-CSF相比，具有降低的体外生物活性的缀合物具有一种或多种改进的性质，例如增加的生物半衰期和增加的嗜中性粒细胞的刺激。

25. 发明申请

US20090203601A1 Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (G-CSF) variant 审中-公开
标题翻译：通过施用多聚乙二醇化粒细胞集落刺激因子（G-CSF）变体治疗嗜中性白细胞减少的方法
公开(公告)号：US20090203601A1
公开(公告)日：2009-08-13
申请号：US12313902
申请日：2008-11-25
申请人： Bobby Soni , Torben Straight Nissen , Mads Roepke , David Gilfoyle
发明人： Bobby Soni , Torben Straight Nissen , Mads Roepke , David Gilfoyle
IPC分类号： A61K38/18 , A61P35/00
CPC分类号： A61K38/193 , A61K47/60 , A61K2300/00
摘要： The invention relates to a method for treating or preventing neutropenia in a patient receiving chemotherapy by administering a multi-PEGylated granulocyte colony stimulating factor (G-CSF) variant on the same day that chemotherapy is administered.
摘要翻译：本发明涉及通过在施用化疗的同一天施用多聚乙二醇化粒细胞集落刺激因子（G-CSF）变体来治疗或预防接受化疗的患者的中性粒细胞减少的方法。

26. 发明申请

US20090030183A1 Interferon Beta-Like Molecules 审中-公开
标题翻译：干扰素β样分子
公开(公告)号：US20090030183A1
公开(公告)日：2009-01-29
申请号：US12206275
申请日：2008-09-08
申请人： Poul Baad Rasmussen , Joern Drustrup , Grethe Rasmussen , Anders Hjelholt Pedersen , Hans Thalsgard Schambye , Kim Vilbour Andersen , Claus Bornaes
发明人： Poul Baad Rasmussen , Joern Drustrup , Grethe Rasmussen , Anders Hjelholt Pedersen , Hans Thalsgard Schambye , Kim Vilbour Andersen , Claus Bornaes
IPC分类号： C07K14/565 , C12P21/02 , C12N15/19 , C12N5/10 , C12N15/85
CPC分类号： A61K9/0019 , A61K9/0073 , A61K31/724 , A61K38/21 , A61K38/215 , A61K47/40 , A61K47/60 , A61K47/6951 , B82Y5/00 , C07K14/565 , A61K2300/00
摘要： The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
摘要翻译：本发明涉及一种表现出干扰素β（IFNB）活性的缀合物，其包含共价连接到IFNB多肽的至少一个第一非多肽部分，所述第一非多肽部分与至少一个引入的和在至少一个除去的氨基酸残基，其包含所述第一非多肽部分的连接基团。第一非多肽部分是例如。聚合物分子或糖部分。该缀合物在治疗中特别有用。本发明还涉及包含至少一个体内糖基化位点的母体IFNB多肽的糖基化变体，其中位于所述糖基化位点附近的所述亲本多肽的氨基酸残基已被修饰以获得具有增加的糖基化的变体多肽作为与母体多肽的糖基化相比。

27. 发明申请

US20090023635A1 Factor VII or VIIa - Like Molecules 有权
标题翻译：因子VII或VIIa-类分子
公开(公告)号：US20090023635A1
公开(公告)日：2009-01-22
申请号：US11928108
申请日：2007-10-30
申请人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
发明人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
IPC分类号： A61K38/17 , C07K14/435 , A61P7/00
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
摘要翻译：提供因子VII（FVII）和因子VIIa（FVIIA）的缀合物，以及制备它们的方法。提供了有助于制备这种缀合物的新型多肽的制备方法。提供了通过施用FVII或FVIIa缀合物治疗的方法。

28. 发明授权

US07419805B2 Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression 失效
标题翻译：编码S99T干扰素γ多肽变体的多核苷酸和表达手段
公开(公告)号：US07419805B2
公开(公告)日：2008-09-02
申请号：US11158848
申请日：2005-06-22
申请人： Anne Dam Jensen
发明人： Anne Dam Jensen
IPC分类号： C12N15/21 , C12N5/00 , C12N15/00 , C07H21/04
CPC分类号： C07K14/57 , A61K38/00
摘要： The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized.Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.
摘要翻译：本发明涉及具有干扰素γ（IFNG）活性的新型干扰素γ多肽变体，其制备方法，包含多肽变体的药物组合物及其在治疗疾病中的用途，特别是用于治疗间质性肺疾病，例如特发性肺纤维化。与huIFNG或其片段的氨基酸序列相比，这些新型多肽变体全部包含取代S99T。通过进行该突变，存在于位置97处的天然存在的N-糖基化位点被显着地更好地利用。优选地，变体包括进一步的修饰，例如。以便在皮下施用时增加这些变体的AUC。

29. 发明授权

US07371543B2 Factor VII or VIIa-like molecules 失效
公开(公告)号：US07371543B2
公开(公告)日：2008-05-13
申请号：US10950747
申请日：2004-09-27
申请人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
发明人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
IPC分类号： C07K14/755
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

30. 发明申请

US20080090764A1 PEGYLATED G-CSF POLYPEPTIDES AND METHODS OF PRODUCING SAME 失效
标题翻译：聚乙二醇化G-CSF多肽及其生产方法
公开(公告)号：US20080090764A1
公开(公告)日：2008-04-17
申请号：US11742445
申请日：2007-04-30
申请人： Carsten GERMANSEN , Bobby SONI , Grethe RASMUSSEN
发明人： Carsten GERMANSEN , Bobby SONI , Grethe RASMUSSEN
IPC分类号： A61K38/19 , C07K14/53 , C12N15/09
CPC分类号： C07K14/535 , A61K38/193 , A61K47/60 , C12P21/02
摘要： A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.
摘要翻译：增加具有连接到赖氨酸残基或N-末端氨基的ε氨基上的至少一个PEG部分和与羟基连接的至少一个PEG部分的聚乙二醇化G-CSF多肽的稳定性和均匀性的方法，包括使多肽经历高于8.0的升高的pH适合于除去连接到羟基上的PEG部分并将pH降低至约8.0或更低的时间; 以及聚乙二醇化G-CSF多肽和根据使用聚乙二醇化G-CSF多肽和组合物在患者中增加嗜中性粒细胞水平的方法和方法产生的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式